JANESVILLE, Wis. (AP) — SHINE Medical Technologies has received regulatory approval to begin building a plant in Janesville that will make medical isotopes for use in millions of diagnostic tests each year.
The Nuclear Regulatory Commission announced that it authorized the construction permit Thursday.
The plant will produce molybdenum-99, known as Mo-99, and other radioisotopes. Mo-99 quickly decays into a form of an isotope called technetium-99m, which is used in scans that can detect cancer and assess blood supply to the heart.
The United States has not commercially produced Mo-99 since 1989.
Monona-based SHINE applied for the construction permit in 2013. The $100 million plant is projected to open in about three years and employ 150 workers. It’s expected to fulfill more than one-fourth of the global need for Mo-99.